FURYLOXAZOLYLACETIC ACID DERIVATIVE, PROCESSES FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION

Abstract: A furyloxazolylacetic acid derivative of the formula: wherein R¹ is lower alkyl, R² is hydrogen atom or lower alkyl, R³ is hydrogen atom or lower alkyl and ring A is phenyl or halogenophenyl, processes for preparing same and phar­ maceutical compositions containing the new compounds, which are useful as a hypolipidemic agent are disclosed.

Description: Furyloxazolylacetic Acid Derivative, Processes for Preparing same and Pharmaceutical Composition This invention relates to a furyloxazolylacetic acid derivative x processes for preparing same and charmaceutical composition. More particularlv, it relates to a furvloxazolvlacetic acid derivative of the formula: EMI1.1 wherein R is lower alkyl, R is hydrogen atom or lower alkyl, R is hydrogen atom or lower alkyl and ring A is phenyl or halogenophenyl. The compound (I) in which R3 is hydrogen can exist in the form of either free acid or a pharmaceutically acceptable salt thereof, and the present invention includes within its scope such pharmaceutically acceptable salt of the compound (I). Besides, the compound (I) in which RÚ and Rê are different from each other can exist in the form of two optical isomers (i.e., d- and l-isomers). The present invention also includes within its scope these optical isomers or a mixture thereof. Hyperlipidemia is known to be one of important causative factors of arteriosclerosis, and various compounds such as dextran sulfate, simfibrate (chemical name: 2-(4-chlorophenoxy)2-methylpropanoic acid 1,3-propanediyl ester), nicomol chemical name: nicotinic acid 1,1,3,3-tetraester with 2-hydroxy-1,1,3,3-cyclohexanetetramethanol), clofibrate (chemical name: 2-(4-chlorophenoxy)-2-methylpropanoic acid ethyl ester) and vitamin E nicotinate have been used for the treatment or prophylaxis of said hyperlipidemia. As a result of investigations, it has now been found that the furyloxazolylacetic acid derivative (I) of the present invention is useful as a hypolipidemic agent. In particular, the furyloxazolylacetic acid derivative (I) shows potent hypolipidemic activity without undesirable side effects such as hepatic dysfunction. Further, the furyloxazolylacetic acid derivative (I) also shows a platelet aggregation-inhibiting activity. Representative examples of the furyloxazolylacetic acid derivative include those of the formula (I) in which the furyl group is 2-furyl or 3-furyl; R1 is lower alkyl 2 such as methyl, ethyl, propyl and butyl; each one of R and R3 is hydrogen atom or lower alkyl such as methyl, ethyl, propyl and butyl; and ring A is phenyl or halogenophenyl such as chlorophenyl, fluorophenyl and bromophenyl. Among them, a preferred subgenus is the compound of the formula (I) in which ring A is phenyl, chlorophenyl or fluorophenyl. Another preferred subgenus is the compound of the formula (I) in which ring A is phenyl, 4-chlorophenyl or 4-fluorophenyl. Further preferred subgenus is the compound of the formula 1 2 (I) in which R is methyl or n-butyl, R is hydrogen atom or methyl, R3 is hydrogen atom, ethyl or n-butyl and ring A is phenyl, 4-chlorophenyl or 4-fluorophenyl. Still further preferred subgenus is the compound of the formula (I) in 1 2 3 which R is methyl, R is hydrogen atom or methyl, R is hydrogen atom or ethyl, and ring A is 4-chlorophenyl. According to the present invention, the compound (I) is prepared by a) aikylating a compound of the formula EMI3.1 wherein R- is lower alkyl and ring A is the same as defined above, to give a compound of the formula: EMI3.2 wherein Rl, RL, R4 and ring A are the same as defined above, and b) if required, hydrolyzing the compound (I-a) to give a compound of the formula: EMI4.1 wherein R, R and ring A are the same as defined above. The alkylation of the compound (11) can be carried out by reacting it with an alkylating agent in a solvent in the presence of an acid acceptor. Examples of the alkylating agent include lower alkyl halide such as methyl iodide, ethyl iodide and butyl bromide, and di(lower alkyl) sulfate such as dimethyl sulfate. Examples of the acid acceptor include an alkali metal alkoxide .such as sodium ethoxide and potassium t-butoxide; an alkali metal hydride such as sodium hydride; and alkali metal hydroxide such as sodium hydroxide and potassium hydroxide; and an alkyl alkali metal such as butyl lithium. Tetrahydrofuran, dimethylformamide, dimethylsulfoxide, acetonitrile, ethanol, methanol or a mixture thereof are suitable as the solvent. The reaction temperature may vary according to the solvent or the acid acceptor to be used, but in general it is preferred to carry out the reaction at a tempetature of -40 to 500C, especially at a temperature of -400 to 20at. The compound (I-a) in which R1is lower alkyl and alkyl and R2 is hydrogn atom may be prepared by reacting the compound (II) with an approximately equimolar amount of the alkylating agent. On the other hand, the compound (I-a) in which RÚ and Rê are lower alkyl may be prepared by using about 2 moles, per mole of the compound (II), of the alkylating agent. Alternatively, in preparing the compound (I-a) in 1 2 which R and R are lower alkyl, said alkylation may be carried out by two steps, i.e., reacting the compound (II) with an about eqimolar amount of the alkylating agent to 1 2 give a compound (I-a) in which R is lower alkyl and R2 is hydrogen atom, and then further reacting said compound with the alkylating agent. In the latter case, the compound 1 2 (I-a) in which R and R are different each other and are lower alkyl may be prepared by the use of different alkylating agents in the first and second alkylation steps. The hydrolysis of the compound (I-a) is accomplished by treating said compound with an acid or an alkali agent in a solvent. The acid includes, for example, mineral acids such as hydrochloric acid or sulfuric acid. On the other hand, the alkali agent includes, for example, alkali metal hydroxides such as sodium hydroxide or potassium hydroxide. Water, alkanol (e.g., methanol, ethanol, propanol), tetrahydrofuran, dioxane and a mixture thereof are suitable as the solvent. It is preferred to carry out the reaction at a temperature of 0 0 1000C, especially at a temperature of 300 to 900C. 3 The compound (I) (R = H) of the present invention can be used for pharmaceutical use in the form of either free acid or a pharmaceutically acceptable salt thereof. Pharmaceutically acceptable salts of the compound (I) (R3 = H) include, for example, alkali metal salts such as sodium and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; salts thereof with amino acids such as lysine, ornithine, arginine and histidine salts; and ammonium salt. Such pharmaceutically acceptable salts may be prepared, for example, by neutrallizing the free acid with a stoichiometrically equimolar amount of a base such as an alkali metal hydroxide, an alkaline earth metal hydroxide, ammonia or a basic amino acid. The compound (I) and a salt thereof can be administered either orally or parenterally. For oral administration, the compound (I) or a salt thereof may be used in the form of tablets, powder, capsules, granules and the like. Rnown medicinal excipients such as calcium carbonate, calcium phosphate, corn starch, potato starch, sugar, lactose, talc, magnesium stearate and so forth may be used in making these pharmaceutical preparations. Alternatively, the compound (I) or a salt thereof may be used for oral administration in the form of aqueous or oily suspensions, solutions, syrups or elixirs. On the other hand, injections and suppositories are suitable for parenteral administration of the compound (I) or its salts, and said injections may be made in the form of solutions or suspensions, if required, in conjunction or admixture with distilled water, essential oil (e.g., peanut oil, corn oil) or non-aqueous solvent (e.g., polyethyleneglycol, polypropyleneglycol, lanoline, coconut oil). The daily dose of the compound (I) or a salt thereof may vary depending on the administration route, the age, weight or conditions of patients, and the severity of diseases to be treated. In general, however, a daily dose of said compound (I) or a salt thereof maybe about 0.05 to 100 mg/kg/day, and a preferred dose thereof for oral administration may be 0.1 to 50 mg/kg/day, especially 5 to 20 mg/kg/day. Concomitantly, the starting compound (II) of the present invention is a novel compound and can be prepared, for example, according to the method shown in the following reaction scheme: EMI8.1 wherein R5 is lower alkyl, XÚ is halogen atom or a group of the formula: EMI8.2 2 3 4 X X and X are halogen atom, and R and ring A are the same as defined above. The reaction of the 2- or 3-furancarboxylic acid derivative (III) with the isocyanoacetate compound (IV) is carried out in a solvent (e.g., tetrahydrofuran, dioxane, dimethylformamide) in the presence of a base such as triethylamine, potassium t-butoxide or 1,8-diazabicyclo 5.4.0 undecene-7 at -50 to 500C. The oxazole derivative (V) thus obtained is saponified with an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide) at 200 to 500C, and the reaction mixture is acidified to give the oxazolecarboxylic acid derivative (VI) which is then treated with a mineral acid (e.g., 2N hydrochloric acid) at 400 to 800C to give the aminoketone compound (VII). Alternatively, the aminoketone compound (VII) may also be prepared by hydrolyzing the compound (V) with a mineral acid, for example, by treating the compound (V) with 4N hydrochloric acid at 500 to 800C. The subsequent reaction of the aminoketone compound (VII) with the acid halide (VIII) is carried out in an aqueous organic solvent (e.g., ethyl acetate, acetone) in the presence of an acid acceptor (e.g., sodium hydroxide, sodium bicarbonate) at -200 to 200C. The N-acylamine derivative (IX) thus obtained is then reacted with the halogenoacetate compound (X) in a solvent (e.g., tetrahydrofuran, dioxane, dimethylformamide, dimethylsulfoxide, acetonitrile) in the presence of a metallic base (e.g., sodium hydroxide, potassium t-butoxide, n-butyl lithium) at -50 to 300C to give the 3-acylaminopropionate derivative (XI). The 3-acylaminopropionate derivative (XI) thus obtained is subjected to dehydrative cyclozation in a solvent (e.g., chloroform, methylene chloride, benzene, tetrahydrofuran) in the presence of a dehydrating agent (e.g., phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride, thionyl chloride, oxalylchloride, phosphorus pentoxide, sulfuric acid, p-toluene sulfonic acid, phosgene, acetic anhydride) at -50 to 1300C to give the furyloxazolylacetate derivative (II). Further, the furyloxazolylacetate derivative (II) may be prepared by the steps of hydrolyzing the compound (II) with an acid or an -alkali agent to give the corresponding free acid and then subjecting it to esterification to give the furyloxazolylacetate derivative (II). The hydrolysis or the esterification may be carried out in a conventional manner. For example, the hydrolysis may be carried out by treating the compound (II) with an aicd (e.g., hydrochloric acid, sulfuric acid) or an alkali (e.g., sodium hydroxide, potassium hydroxide) in a solvent (e.g., water, methanol, ethanol, tetrahydrofuran, dioxane or a mixture thereof). On the other hand, the esterification may be conducted, for example, by reacting the free acid with an alkanol of the 4 . 4 formula: R -OH (wherein R is the same as defined above) in the presence of a halogenating agent (e.g., thionyl chloride, oxalyl chloride, phosphorus tribromide, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride). Practical and presently-preferred embodiments of the present invention are illustratively shown in the following lines. Throughout the specification and claims the term "lower alkyl" should be interpreted as referring to an alkyl group of one to 4 carbon atoms. Experiment 1 (Hypolipidemic activity) A test compound (50 mg %) was added to a commercial diet, and male SD rats (body weight: 120 - 140 g, a group of 5 rats) were fed with the diet ad libitum for one week. After the experimental period, blood was collected from the tail vein of the rats under ether anesthesia. Then, serum cholesterol and serum triglyceride were measured according to the methods of Zak (Amr. J. Clin, Pathos., Vol. 24, page 1307 (1954)) and Van Handel-Silversmit (J. Lab. & Clin. Med., Vol. 50, page 152 (1957)), respectively. Based on the results obtained above, the decrease (%) in serum cholesterol or triglyceride were calculated by the following formula: EMI11.1 <tb> <SEP> Serum <SEP> cholesterol <SEP> or <tb> <SEP> triglyceride <SEP> (mg/ml) <tb> Decrease <SEP> (%) <SEP> in <SEP> serum <SEP> triglyceride <SEP> (mg/ml) <SEP> <tb> cholesterol <SEP> or <SEP> tri- <SEP> = <SEP> 1 <SEP> - <SEP> in <SEP> the <SEP> medicated <SEP> group <SEP> x <SEP> 100 <tb> <SEP> Serum <SEP> cholesterol <SEP> or <tb> glyceride <SEP> triglyceride <SEP> (mg/ml) <tb> <SEP> in <SEP> the <SEP> control <SEP> group <tb> (Results) The results are shown in the following Table 1. Table 1 Decrease Decrease (%) in (%) in Test compound serum serum choles- trigly terol ceride (The compounds of the present invention) 2- ±2- (4-chlorophenyl ) - 5-(2-furyl)-4-oxazolyl)- 14 34 propionic acid Ethyl 2- ±2- (4-chlorophenyl )- 5-(2-furyl)-4-oxazolyl)- 15 22 propionate 2- ±2-.( 4-chlorophenyl ) - 5-(2-furyl)-4-oxazolyl)- 16 54 2-methylpropionic acid Ethyl 2- ±2- (4-chlorophenyl ) - 5-(3-furyl)-4-oxazolyl)- 22 45 propionate (Positive control) Clofibrate 15 16 Experiment 2 (Platelet aggregation-inhibiting activity) Blood was collected from the abdominal aorta of male SD rats (body weight: 250 - 300 g) which were anesthetized with ether. Nine volumes of said blood were mixed with one volume of an aqueous 3.8 z (w/v) trisodium citrate solution, and the mixture was centrifuged at 500 x g for 5 minutes to give platelet-rich plasma (hereinafter referred to as "PRP") as the supernatant solution. The bottom layer was further centrifuged at 1000 x g for 10 minutes to give platelet-poor plasma (hereinafter referred to as "PPP") as the supernatant solution. PRP was diluted with PPP so that the blood platelet count was 8 - 10 x 10 5/mum3. Then, a mixture of 200 1 of said diluted PRP and 25jkl of a test compound solution (final concentration: 100 g/ml) was introduced into a glass cell of SIENCO aggregometer (Sienco Inc., Morrison, Colo. Model DP-247-D). After the mixture was stirred at 1100 rpm at 370C for 2 minutes, 25 1 of a collagen solution (prepared by Holmsen's method described in Biochim. Biophys. Acta, Vol. 186, page 254(1969)) was added thereto, and the percentage inhibition of platelet aggregation was calculated in accordance with the following formula from the degree of the platelet aggregation which was estimated by Born's method (Nature, 194, page 927(1969)). EMI13.1 <tb> <SEP> Degree <SEP> of <SEP> platelet <tb> <SEP> aggregation <SEP> which <tb> Percentage <SEP> was <SEP> estimated <SEP> by <tb> inhibition <SEP> of <SEP> = <SEP> 1 <SEP> adding <SEP> test <SEP> compound <SEP> x <SEP> 100 <tb> platelet <SEP> Degree <SEP> of <SEP> platelet <tb> aggregation <SEP> aggregation <SEP> which <SEP> was <tb> <SEP> estimated <SEP> without <tb> <SEP> adding <SEP> test <SEP> compound <tb> Further, on the basis of said percentage inhibition calculated above, the platelet aggregation-inhibiting activity of the test compound was expressed as (-) if the test compound showed less than 10 % inhibition of platelet aggregation; or (+) if the test compound showed not less than 10 % inhibition of platelet aggregation. (Results) The results are shown in the following Table 2. Table 2 Platelet aggregation Test compounds inhibiting activity (The compounds of the present invention) Ethyl 2- ±2- (4-chlorophenyl ) - 5- (3-furyl) -4-oxazolyl) - + propionate Ethyl 2-(2-(4-chlorophenyl)- 5- (2-furyl ) -4-oxazolyl3 - + propionate (Positive control) Clofibrate Example 1 4.8 g of 60 % sodium hydride are suspended in 200 ml of dimethylformamide, and a solution of 33.2 g of ethyl 2-L2-(4-chlorophenyl)-5-(2-furyl)-4-oxazolyl]acetate in 200 ml of tetrahydrofuran is added dropwise thereto at -30 to -200C. Then, 17 g of methyl iodide are added dropwise to the mixture, and the mixture is stirred at -100 to 0 C for 30 minutes. 5 ml of acetic acid are added to the reaction mixture, and the mixture is distilled to remove the solvent. 600 ml of ethyl acetate and 500 ml of water are added to the residue, the mixture is stirred, and then an organic layer is collected therefrom. The organic layer is washed with a saturated sodium bicarbonate solution and a saturated sodium chloride solution, dried and then condensed. 50 ml of ethanol are added to the residue, and crystalline precipitates are collected by filtration. 30.5 of ethyl 2-t2-(4-chloro- phenyl)-5-(2-furyl)-4-oxazolyl)propionate are obtained as colorless needles. Yield: 88% M.p. 97 - 97.50C IR ; max (cm 3 : 1740 NMR (CDCl ) : 1.20 (3H, t, J=7.5 Hz), 1.63 (3H, 3 d, J=7.5 Hz), 3.8 - 4.4 (3H, m), 6.43 (1H, dd, J=3.5 and 1.5 Hz), 6.65 (1H, d, J=3.5Hz), 7.32 and 7.92 (2H, each A2 ' B2 ', J=8Hz), 7.45 (1H, dd, J=1.5 Hz) Mass (m/e) : 345 (M ) Example 2 5.0 g of n-butyl 2-(2-(4-chlorophenyl)-5-(2-furyl)-4- oxazolyl)acetate, 30 ml of tetrahydrofuran, 0.8 g of sodium hydride, 50 ml of dimethylformamide and 2.5 g of methyl iodide are treated in the same manner as described in Example 1. 5.2 g of n-butyl 2-(2-(4-chlorophenyl)-5-(2-furyl)-4- oxazolyl) propionate are thereby obtained as needles. Yield: 93 % M.p. 48 - 500C IR max (cm-1) : 1735 Mass (m/e) : 373 (M+, 100) Example 3 1.65 g of ethyl 2-t2-(4-chlorophenyl)-5-(3-furyl)-4- oxazolyl)acetate, 10 ml of tetrahydrofuran, 0.25 g of sodium hydride, 30 ml of dimethylformamide and 0.84 g of methyl iodide are treated-in the same manner as described in Example 1. 1.31 g of ethyl 2-(2-(4-chlorophenyl)-5-(3-furyl)-4-oxazolyl] propionate are thereby obtained. Yield: 73 % M.p. 108 - 1090C IR ) nuJol (c -1) : 1735 Mass (m/e) : 345 (M+, 90) Example 4 1.57 g of ethyl 2-t2-(4-fluorophenyl)-5-(2-furyl)-4- oxazolylgacetate and 0.78 g of methyl iodide are dissolved in 3 ml of tetrahydrofuran, and the solution is added dropwise to 10 ml of an ethanol solution containing 0.41 g of sodium ethoxide. Said dropwise addition is carried out at 50 100C. Then, the mixture is treated in the same manner as described in Example 1. 0.74 g of ethyl 2-±2-(4-fluorophenyl)- 5-(2-furyl)-4-oxazolylDpropionate are thereby obtained as needles. Yield: 45 % M.p. 95 - 960C IR ; nut owl (cm-1) : 1735 max Mass (m/e) : 329 (M , 100) Exmaple 5 4.97 g of ethyl 2-t2-(4-chlorophenyl)-5-(2-furyl)-4- oxazolylgacetate are dissolved in a mixture of 50 ml of dimethylformamide and 30 ml of tetrahydrofuran. 2.16 g of 50 8 sodium hydride are added to the mixture at -150C. The mixture is stirred for 5 minutes, and then 1.86 ml of methyl iodide are added thereto. After the temperature of the mixture is raised gradually to room temperature, the mixture is stirred at the same temperature for 5 hours. 1 ml of acetic acid is added to the mixture, and the mixture is distilled to remove tetrahydrofuran. 300 ml of ethyl acetate and 200 ml of water are added to the residue. The mixture is shaken, and the organic layer is collected. The organic layer is washed with a saturated sodium bicarbonate solution and a saturated sodium chloride solution, dried and then condensed. 20 ml of ethanol are added to the residue, and the crystalline precipitates are collected by filtration. 4.50 g of ethyl 2-(2-(4-chlorophenyl)-5-(2-furyl)-4-oxazolyl3- 2-methylpropionate are obtained as colorless needles. Yield: 84 % M.p. 89 - 900C IR nujol (Cm ) : 1730 NMR (CDC13) : 1.07 (3H, t, J= 7Hz), 1.68 (6H, s), 4.02 (2H, q, J=7Hz), 6.44 (lH, dd, J= 2 and 4Hz), 6.59 (1H, d, J= 4Hz), 7.34 and 7.93 (2H each, A 'B ', J- 9Hz), 22 7.44 (lH, d, J=2Hz) Mass (m/e) : 359 (M , 90) Example 6 3.32 g of ethyl 2-(2-(4-chloropheyl)-5-(3-furyl)-4- Cxazolyl)acetate, 50 ml of dimethylformamide, 20 ml of tetrahydrofuran, 0.50 g of 50 % sodium hydride and 1.70 g of methyl iodide are treated in the same manner as described in Example 5. 2.7 g of ethyl 2-±2-(4-chlorophenyl)-5-(3-furyl)- 4-oxazolyl)-2-methylpropionate are thereby obtained as needles. Yield: 75 % M.p. 71 - 720C IR Cm nuzol (cm¯l) 1720 Max (m/e) : 359 (M , 70) Example 7 1.70 g of ethyl 2-c2-(4-chlorophenyl)-5-(2-furyl)-4- oxazolylJpropionate are dissolved in a mixture of 10 ml of water and 50 ml of methanol, and 1.12 g of potassium hydroxide are added thereto. The mixture is stirred at 60"C for one hour. The reaction mixture is condensed to remove methanol, and 30 ml of water are added to the residue. The aqueous solution is washed with ether, and the solution is acidified to pH 3 with 10 % hydrochloric acid. The aqueous solution is extracted with ethyl acetate, and the extract is dried and then condensed. Diisopropyl ether is added to the residue, and the crystalline precipitates are collected by filtration. 1.0 g of 2-t2-(4-chlorophenyl)-5-(2-furyl)-4- oxazolyl)propionic acid is obtained. Yield: 64 e t4.p. 186 - 1870C IR nujol 1) : 1710 NMR (CDCl -DMSO-d 3 6 1.6 (3H, d, J= 7.5Hz), 4.12 (1H, q, J= 7.5 Hz), 6.47 (lH, m), 7.1 - 8.1 (6H, m) + Mass (m/e) : 317 (M , 20 Example 8 A mixture of 2.0 g of ethyl 2-(2-(4-chlorophenyl)-5 (2-furyl) -4-oxazolyl) -2-methylpropionate, 0.47 g of potassium hydroxide, 30 ml of methanol and 10 ml of water is refluxed for 5 hours on a water bath. Then, the reaction mixture is treated in the same manner as described in Example 7. 1.58 g of 2- ±2- (4-chlorophenyl ) -5- (2-furyl) -4-oxazolyl) -2-methyl propionic acid are thereby obtained as needles. Yield: 86 M.p. 186 - 1890C IR nujol (cm1) : 1720 NMR (DMSO-d6) : 1.61 (6H, s), 6.6 - 7.0 (2H, m), 7.52 and 7.98 (2H each A2 'B ', J= 8Hz), 2 7.83 (lH, broad s) Mass (m/e) : 331 (M+, 60) Example 9 0.14 g of 60 % sodium hydride is suspended in 20 ml of tetrahydrofuran, and a mixture of 3.3 g of ethyl 2-(2-(4 chlorophenyl)-5-(2-furyl)-4-oxazolyl) acetate, 1.6 g of n-butyl bromide and 10 ml of dimethylformamide is added dropwise thereto at -400 to -200C. After the temperature of the mixture is raised gradually to room temperature, the mixture is stirred at the same temperature for 2 hours. Then, the reaction mixture is treated in the same manner as described in Example 1. 2.28 g of ethyl 2-t2-(4-chlorophenyl)- 5-(2-furyl)-4-oxazolyl) hexanoate are thereby obtained. M.p. 76 - 780C IR nujol (cm¯l) 1730 ax + Mass (m/e) : 387 (M , 100) Example 10 0.096 g of 50 % sodium hydride is suspended in 10 ml of dimthylformamide, and a mixture of 0.65 g of n-butyl 2- (2-phenyl-5-(2-furyl)-4-oxazolyl) acetate, 0.31 g of methyl iodide and 10 ml of tetrahydrofuran is added dropwise thereto at -30 to -10 C. After the temperature of the mixture is raised gradually to room temperature, the mixture is stirred at the same temperature for 30 minutes. Then, the reaction mixture is treated in the same manner as described in Example 1. 0.50 g of n-butyl 2- (2-phenyl-5-(2-furyl)-4-oxazolyl) propionate are thereby obtained. Yield: 74 % M.p. 43 -44 C IR ; max (cm-1) : 1735 Mass (m/e): 339 (M+, 60) (Preparation of the starting compounds) preparation 1 (1) To a mixture of 10 g of (2-furylcarbonyl)methylamine hydrochloride, 12.5 g of sodium bicarbonate, 200 ml of ethyl acetate and 100 ml of water are dropwise added 12.0 g of 4-chlorobenzoyl chloride at a temperature below 10 C under stirring. The mixture is stirred at room temperature for 3 hours. Then, the ethyl acetate layer is collected, washed with water and dried. Said ethyl acetate layer is evaporated under reduced pressure to remove solvent. 16.0 g of N- (4-chlorobenzoyl )- (2rfurylcarbonyl)methylamine are thereby obtained. Yield: 98.2 % M.p. 1380 - 1390C IR ; mux (cm 1) : 3400, 1680, 1660, 1595 (2) To a solution of 40 g of N-(4-chlorobenzoyl) (2-furylcarbonyl)methylamine in 160 ml of dimethylformamide are added 7.2 g of 61 % sodium hydride at -50 to -400C under stirring. The mixture is further stirred at the same temperature for 5 minutes. 27.9 g of ethyl bromoacetate are added to the mixture at -50 to -400C, and said mixture is stirred at the same temperature for one hour and further stirred at about 0 C for one hour. After the reaction is completed, the mixture is neutrallized with acetic acid. Then, water is added to the mixture and said mixture is extracted with ethyl acetate. The extract is washed with an aqueous sodium bicarbonate solution and water, successively. Said extract is dried and then evaporated under reduced pressure to remove solvent. The residue is crystallized with a mixture of isopropyl ether and n-hexane, whereby 37.0 g of ethyl 3-(4-chlorobenzoylamino)-3-(2-furylcarbonyl)- propionate are obtained. Yield: 70 % M.p. 1000 - 1020C IR ; nujol (cam¯1) : 3300, 3100, 1738, 1680 max 1630, 1595 (3) 37 g of ethyl 3-(4-chlorobenzoylamino)-3-(2furylcarbonyl)propionate are dissolved in 150 ml of chloroform. 64.9 g of phosphorus oxychloride are added dropwise to the solution at room temperature, and the mixture is refluxed at 600 to 700C for 8 hours under stirring. After the reaction is completed, the mixture is poured into ice-water. The aqueous mixture is neutrallized with sodium bicarbonate and then extracted with ethyl acetate. The extract is washed with water, dried, treated with activated charcoal and then evaporated under reduced pressure to remove solvent. The residue is crystallized with diisopropyl ether, and then recrystallized from ethanol. 30 g of ethyl 2 ±2- (4-chlorophenyl) -5- (2-furyl )-4-oxazolyl) acetate are thereby obtained. Yield: 85.5 % M.p. 1050 - 1060C IR ; nujoi (cm ) : 1723, 1600 Preparation 2 (1) 6.0 g of potassium tert.-butoxide are dissolved in 60 ml of tetrahydrofuran, and 4.4 g of methyl -isocyano- acetate are added dropwise thereto at -500C under stirring. The mixture is stirred at the same temperature for one hour. Then, 5.8 g of 3-furylcarbonyl chloride are added dropwise to the mixture at -500C under stirring, and said mixture is further stirred for 2 hours. After the reaction is completed, the mixture is adjusted to a pH of 3 to 4 with acetic acid and then evaporated under reduced pressure to remove solvent. The residue is extracted with ethyl acetate, and the extract is washed with water and an aqueous sodium bicarbonate solution, successively. Said extract is dried and evaporated under reduced pressure to remove solvent. The residue is washed with isopropyl ether, whereby 6.5 g of methyl 5-(3-furyl)oxazole-4-carboxylate are obtained. Yield: 75.4 % M.p. 870 - 880C IR Cm ai (cm ) : 3120, 1695 (2) 3 g of methyl 5-(3-furyl)oxazole-4-carboxylate and 2.6 g of 85 % potassium hydroxide are dissolved in 100 ml of methanol, and the solution is stirred at room temperature overnight. Then, the reaction mixture is evaporated under reduced pressure to remove methanol, and the residue is acidified with dil. hydrochloric acid. The precipitated crystals are collected by filtration, washed with cold water and then dried. 2.6 g of 5-(3-furyl)oxazole-4-carboxylic acid are thereby obtained. Yield: 93.7 % M.p. 1890 - 1910C IR > nuzol (Cm-l) 3110, 1700, 1600 (3) A mixture of 3.0 g of 5-(3-furyl)oxazole-4-carboxylic acid and 50 ml of 3N hydrochloric acid is stirred at 400 to 50 C for 6.5 hours. Then, the mixture is condensed under reduced pressure, and the residue is crystallized with acetone. The precipitated crystals are collected by filtration, whereby 2.2 g of (3-furylcarbonyl)methylamine hydrochloride are obtained. Yield: 80 % M.p. 1960 - 198 C. IR# nujol (cm ) : 3110, 1680, 1560 (4) 5 g of (3-furylcarbonyl)methylamine hydrochloride, 6.0 g of sodium bicarbonate and 6.0 g of 4-chlorobenzoyl chloride are treated in the same manner as described in Preparation 1-(1). 8.2 g of N-(4-chlorobenzoyl)-(3-furylcarbonyl)methylamine are thereby obtained. Yield: 100 % M.p. 1520 - 1540C (cm-1) (cm -1) 3350, 3110, 1675, 1635, 1595 (5) 8.3 g of N-(4-chlorobenzoyl)- (3-furylcarbonyl)- methylamine, 1.S g of 61 % sodium hydride and 5.8 g of ethyl bromoacetate are treated in the same manner as described in Preparation 1-(2). 8.5 g of ethyl 3-(4-chlorobenzoylamino)3-(3-furylcarbonyl)propionate are thereby obtained. Yield: 77.3 % M.p. 930 - 950C (decomp.) ( # nujol -1 IR 5 max (cm ) : 3340, 3100, 1705, 1670, 1640 (6) 7.0 g of ethyl 3-(4-chlorobenzoylamino)-3-(3furylcarbonyl)propionate, 35 ml of chloroform and 12.3 g of phosphorus oxychloride are treated in the same manner as described in Preparation 1-(3). 5.7 g of ethyl 2-(2-(4- chlorophenylj-5-(3-furyl)-4-oxazolyl) acetate are thereby obtained. Yield: 85.5 9s M.p. 1240 - 1250C IR; max (cm ) : 3130, 1725 max Preparation 3 (1) A solution of 0.4 g of potassium hydroxide in 30 ml of methanol is added to 1.0 g of ethyl 2-C2-(4-chloro- phenyl)-5-(2-furyl)-4-oxazolyl]acetate at 5 to 100C. The mixture is stirred at room temperature for 10 hours. Then, the precipitates are collected by filtration, washed with ether and then dried. 0.85 g of potassium 2-[2-(4-chloro phenyl)-5-(2-furyl)-4-oxazolyl] acetate is obtained. Yield: 80.2 % M.p. 2500C IR Cm nuJol (Cml) : 1610 (2) 0.85 g of potassium 2-(2-(4-chlorophenyl)-5- (2-furyl)-4-oxazoyl)acetate is dissolved in 20 ml of water, and the solution is acidified with hydrochloric acid. The precipitates are collected by filtration and then recrystallized from ethanol. 0.69 g of 2-(2-(4-chlorophenyl)-5-(2-furyl)-4- oxazolyl) acetic acid is thereby obtained. Yield: 90.9 % M.p. 1910 - 1940C (decomp.) nujol -1 IR (cm-1 ) : 1720 max (3) To a solution of 2.0 g of 2-t2-(4-chlorophenyl)- 5-(2-furyl)-4-oxazolyl)acetic acid in 20 ml of chloroform are added 2.0 g of thionyl chloride at room temperature. The mixture is refluxed for 3 hours under stirring. After cooling, 0.6 g of n-butanol is added to the mixture, and said mixture is stirred at room temperature for 6 hours. After the reaction is completed, the mixture is evaporated under reduced pressure to remove solvent. The residue is extracted with ethyl acetate, and the extract is washed with an aqueous sodium bicarbonate solution and water, successively. Then, the extract is dried and then evaporated under reduced pressure to remove solvent. The residue is recrystallized from ethanol, whereby 1.5 g of n-butyl 2-(2-(4-chlorophenyl)- 5-(2-furyl)-4-oxazolyl)acetate are obtained. Yield: 62.3 % M.p. 960 - 970C IR 5 nujol (cm 1) 1 3050, 1730 max ) Preparation 4 (1) 23.4 g of (2-furylcarbonyl)methylamine hydrochloride, 29.3 g of sodium bicarbonate and 23.0 g of 4-fluorobenzoyl chloride are treated in the same manner as described in Preparation 1-(1). 24.0 g of N-(4-fluorobenzoyl)-(2-furylcarbonyl)methylamine are thereby obtained. Yield: 66.8 % M.p. 153 - 1550C IR ; nmu3aoxl cm ) : 3410, 3100, 1680, 1655 (2) 24.0 g of N-(4-fluorobenzoyl)-(2-furylcarbonyl)methylamine, 4.7 g of 61 % sodium hydride and 18.4 g of ethyl bromoacetate are treated in the same manner as described in Preparation 1-(2). 21.0 g of ethyl 3-(4-fluorobenzoylamino)-3-(2-furylcarbonyl)propionate are thereby obtained. Yield: 64.8 % M.p. 95.50 - 970C IR nujol (cm ) : 3300, 1725, 1690, 1640, 1600 (3) 6.67 g of ethyl 3-(4-fluorobenzoylamino)-3-(2furylcarbonyl)propionate, 35 ml of chloroform and 12.3 g of phosphorus oxychloride are treated in the same manner as described in Preparation 1-3. 4.98 g of ethyl 2-12-(4-fluoro- phenyl)-5-(2-furyl)-4-oxazolyl)acetate are thereby obtained. Yield: 78.9 % M.p. 1100 - 1110C IR m maJ (cm ) : 3110, 1725 Preparation 5 (1) 3.4 g of (2-furylcarbonyl)methylamine hydrochloride, 4.4 g of sodium bicarbonate and 3.3 g of benzoyl chloride are treated in the same manner as described in Preparation 1-(1). 4.0 g of N-benzoyl-(2-furylcarbonyl)methylamine are thereby obtained. Yield: 83.3 % M.p. 1320 - 1330C IR 5 nujol -1 3400, 3100, 1675, 1600 max (cm (2) 4.0 g of N-benzoyl-(2-furylcarbonyl)methylamine, 0.8 g of 61 % sodium hydride and 3.2 g of ethyl bromoacetate are treated in the same manner as described in Preparation 1-(2). 4.0 g of ethyl 3-benzoylamino-3-(2-furylcarbonyl)propionate are thereby obtained. Yield: 72.7 % M.p. 75 - 760C IR 5 nujol (cm ) : 3300, 1715, 1680, 1640 max (3) 6.31 g of ethyl 3-benzoylamino-3-(2-furylcarbonyl)propionate, 35 ml of chloroform and 12.3 g of phosphorus oxychloride are treated in the same manner as described in Preparation 1-(3). 4.47 g of ethyl 2-t2-phenyl-5-(2-furyl)-4-oxazolyljacetate are thereby obtained. Yield: 75 % M.p. 790 - 800C IR nujol (cm-1) 3130, max (cm ) : 3130, 1735 Preparation 6 (1) 3.5 g of ethyl 2-t2-phenyl-5-(2-furyl)-4-oxazolyl)- acetate are dissolved in a mixture of 50 ml of methanol and 10 ml of water, and 1.2 g of sodium hydroxide are added thereto. The mixture is stirred at room temperature for 10 hours. After the reaction is completed, the mixture is condensed under reduced pressure to remove methanol. Water is added to the residue, and the aqueous mixture is adjusted to pH 2 with conc. hydrochloric acid, and then extracted with ethyl acetate. The extract is washed with water, dried and then evaporated under reduced pressure to remove solvent. The resude is recrystallized from ethanol, whereby 2.5 g of 2-±2-phenyl-5-(2-furyl)-4-oxazolyl)acetic acid are obtained. Yield 78.1 % M.p. 1750 - 1770C IR nujol (cm-1 ) : 3100, 1690 max (2) 5.86 g of 2-(2-phenyl-5-(2-furyl)-4-oxazolyl)acetic acid, 50 ml of chloroform, 4.8 g of thionyl chloride and 2.5 g of n-butanol are treated in the same manner as described in Preparation 3-(3). 4.22 g of n-butyl 2-(2-phenyl-5-(2- furyl)-4-oxazolyl)acetate are thereby obtained. Yield: 64.9 % M.p. 53 - 540C IR#max l (cm-1): 1720 Mass (m/e): 325 (M+, 75)

Claims: s 1. A compound of the formula: EMI30.1 wherein R is lower alkyl, R is hydrogen atom or lower alkyl, R is hydrogen atom or lower alkyl and ring A is phenyl or halogenophenyl. 2. The e compound of Claim 1, in which R3 is hydrogen atom. or a pharmaceutically acceptable salt thereof. 3. The compound of Claim 1, in which Ring A is phenyl, chlorophenyl or fluorophenyl. 4. The compound of Claim 3, in which R3 is hydrogen atom or a pharmaceutically acceptable salt thereof. 5. The compound of Claim 3, in which ring A is phenyl, 4-chlorophenyl or 4-fluorophenyl. 6. The compound of Claim 5.,in which R3 is hydrogen atom, or a pharmaceutically acceptable salt thereof. 7. The compound of Claim 5, in which R1 is methyl or n-butyl, R2 is hydrogen atom or methyl and R3 is hydrogen atom, ethyl or n-butyl. 8. The compound of Claim 7, in which R3 is hydrogen atom or a pharmaceutically acceptable salt thereof. 9. The compound of Claim 7, in which R1 is methyl, R3 is hydrogen atom or ethyl and ring A is 4-chlorophenyl. 10. The compound of Claim 9 which is ethyl 2- ±2- (4-chlorophenyl)-5- (3-furyl)-4-oxazolyl) propionate. 11. The compound of Claim 9, which is 2- ±2- (4-chlorophenyl )-5- (2-furyl)-4-oxazolyl) -2-methyl- propionic acid.r a pharmaceutically acceptable salt thereof. 12. The compound of Claim X, which is ethyl 2- ±2- (4-chlorophenyl ) -5- (2-furyl ) -4-oxazolyl) propionate. 13. The compound of Claim 9, which is 2-±2-(4- chlorophenyl-5- (2-furyl )-4-oxazolyl)propionic acid or a pharmaceutically acceptable salt thereof 14. A process for prearing a compound of the formula: EMI31.1 wherein R is lower alkyl, R is hydrogen atom or lower alkyl, R is hydrogen atom or lower alkyl and ring A is phenyl or halogenophenyl, which comprises a) alkylating a compound of the formula: EMI32.1 wherein R is lower alkyl and ring A is the same as defined above, to give a compound of the formula: EMI32.2 wherein RI R , R and ring A are the same as defined above, and b) if required, hydrolyzing the compound (I-a) to give a compound of the formula: EMI32.3 WneZeln K, R ana ring A are the same as defined above. 15. The process according to Claim 14, wherein the compound of the formula (I-b) is further converted into a pharmaceutically acceptable salt thereof. 16. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of the formula: EMI33.1 wherein R is lower alkyl, R is hydrogen atom or lower 3 alkyl, R is-hydrogen atom or lower alkyl and ring A is phenyl or halogenophenyl, and a pharmaceutically acceptable carrier therefor. 17. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of the formula: EMI33.2 wherein R- is lower alkyl, R is hydrogen atom or lower alkyl and ring A is phenyl or halogenophenyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

Inventors: MATSUMOTO, KAZUO, TAKASHIMA, KOHKI
Applicants: TANABE SEIYAKU CO., LTD.
Application year: 1984
Main classification: C07D413
IPC codes: C07D413, C07D307, C07D417, A61P7, A61P3, A61K31